RxDoctor Payments Data

Jayant Bagai, MD

Interventional Cardiology · Nashville, TNNPI 1073607784

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Boston Scientific at 31.6% of the total. 2025 is the largest year on record at $661, 7.8 times the $85 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in TN, where the typical reported total is $7,646.

$1,492in general payments, 2019–2025

Across 15 payments — averaging $99.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$471
  • Angiodynamics, Inc.$463
  • Penumbra, Inc.$323
  • Inari Medical, Inc.$189
  • Medtronic$19
  • Abbott$15
  • plus $13 from 1 others
$41,225in research payments, 2019–2025

Across 15 payments — averaging $2748.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$41K

What the payments were for

  • Travel & lodging$534%
  • Food & beverage$1,43996%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,492 in reported general payments places this provider in the 10th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$75,226
Medicare patients
787
Services billed
1,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab28$30,248
EntrestoSacubitril/Valsartan14$10,606
Ezetimibe32$1,338
Metoprolol Succinate75$1,167
Atorvastatin Calcium40$430
Losartan Potassium23$314
Rosuvastatin Calcium26$293
Lisinopril21$203
Carvedilol16$120
Metoprolol Tartrate35$113
Nitroglycerin11$101
ClopidogrelClopidogrel Bisulfate14$88
Amlodipine Besylate15$49

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →